Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 20

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 20
---
 Securities Act and the rules of the Financial Industry Regulatory Authority,
Inc., or FINRA.

Depositary
Shares representing our Ordinary Shares sold pursuant to the registration statement of which this prospectus is a part will be authorized
for listing and trading on The NASDAQ Capital Market. The applicable prospectus supplement will contain information, where applicable,
as to any other listing, if any, on The NASDAQ Capital Market or any securities market or other securities exchange of the securities
covered by the prospectus supplement. Underwriters may make a market in our Depositary Shares, but will not be obligated to do so and
may discontinue any market making at any time without notice. We can make no assurance as to the liquidity of or the existence, development
or maintenance of trading markets for any of the securities.

In
order to facilitate the offering of the securities, certain persons participating in the offering may engage in transactions that stabilize,
maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve
the sale by persons participating in the offering of more securities than we sold to them. In these circumstances, these persons would
cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option. In
addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing the applicable security in
the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed
if the securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be
to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These
transactions may be discontinued at any time.

The
underwriters, dealers and agents may engage in other transactions with us, or perform other services for us, in the ordinary course of
their business.

| 13 |

<div align='center'>DESCRIPTION OF SHARE CAPITAL</div>

The following describes our issued share capital, summarizes the material provisions of our Articles of Association and highlights certain differences in corporate law in the United Kingdom and the United States. This description of our share capital and summary of our Articles of Association is not complete, and is qualified by reference to our Articles of Association. You should read our Articles of Association, which are filed as an exhibit to the registration statement of which this prospectus forms a part, for the provisions that are